Sling Therapeutics Secures $123 Million in Series C Funding Led by Forbion

Sling Therapeutics Raises Series C Funding

Sling Therapeutics, based in Ann Arbor, Michigan, has successfully raised $123 million in a Series C funding round. The round was led by Forbion, with additional participation from TPG Life Sciences Innovations and Sectoral Asset Management. Sling Therapeutics is known for its work in developing treatments for autoimmune and inflammatory diseases.

Leadership and Vision

Ryan Zeidan, the CEO of Sling Therapeutics, is at the helm of the company's strategic direction. This significant infusion of capital is expected to support the company’s growth initiatives and further its mission to provide innovative therapies in its field.

Use of Funds

While specific plans for the use of the new funds were not detailed, such investments typically support clinical development, regulatory activities, and potential expansions in research and development capabilities.

Investor Perspective

Forbion's involvement as the lead investor underscores the confidence in Sling Therapeutics' potential and strategic direction. The participation of TPG Life Sciences Innovations and Sectoral Asset Management further highlights the interest and support from major players in the life sciences investment community.